Russia rejects Abbott Laboratories' plan to buy Petrovax
MOSCOW (Reuters) - Russia's government commission on foreign investment has rejected U.S. Abbott Laboratories' plan to buy Russian pharmaceutical producer Petrovax, the head of the Russian antitrust regulator said on Friday.
"The commission has reviewed the question about the sale to U.S. company Abbott of Petrovax Pharm. As a result of very lengthy discussion the U.S. company was denied to make this deal," Igor Artemyev, head of the Federal Anti-Monopoly Service (FAS), told reporters.
Abbott Laboratories filed for permission to buy the Russian vaccine developer and producer last year.
Abbott Laboratories spokeswoman Irina Gushchina said the company had not received any official information regarding the state of its application.
(Reporting by Darya Korsunskaya; Writing by Maria Kiselyova; Editing by Megan Davies)
- Air strike kills 15 civilians in Yemen by mistake: officials
- North Korea executes leader's powerful uncle in rare public purge |
- Insight: In Yemen, al Qaeda gains sympathy amid U.S. drone strikes
- Storm to cloak Midwest to Northeast in snow, freezing rain
- Twitter backtracks on block feature after users revolt |
Thousands line up to say goodbye to Nelson Mandela, whose body is lying in state in Pretoria. Slideshow